Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 3/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1016154 | 1.00 | PDE4B (0.53) | PDE4BGPR119NAMPTSTSTGFBR1 | |
| SCHEMBL18937651 | 0.92 | PDE4B (0.60) | PDE4BGPR119NAMPTKDM4EMAPT | |
| SCHEMBL20748135 | 0.85 | PDE4B (0.53) | PDE4BGPR119NAMPTMAPT | |
| SCHEMBL28301552 | 0.85 | PDE4B (0.53) | PDE4BGPR119NAMPTMAPT | |
| SCHEMBL1015081 | 0.84 | PDE4B (0.47) | PDE4BGPR119NAMPTSTSMMP1 | |
| SCHEMBL1015080 | 0.84 | PDE4B (0.47) | PDE4BGPR119NAMPTSTSMMP1 | |
| SCHEMBL3854559 | 0.84 | NAMPT (0.61) | PDE4BGPR119NAMPTSTSKDM4E | |
| SCHEMBL12321142 | 0.81 | PDE4B (0.60) | PDE4BGPR119NAMPTKDM4EMAPT | |
| SCHEMBL17530337 | 0.81 | GPR119 (0.62) | PDE4BGPR119 | |
| SCHEMBL20607546 | 0.81 | RORC (0.48) | PDE4BGPR119NAMPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081890-B1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | HTR6, HTR1B, HTR1F | PDE4B 1026/4885GPR119 138/4885NAMPT 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.